OCUL

Ocular Therapeutix, Inc. (OCUL) | Rumor.io

Ocular Therapeutix

OCUL

Attention (50-day avg)0%

Attention rank (50-day avg)#742

Bullish sentiment (50-day avg)64%

Price to earnings ratio-5.39

Market capitalization1.7B

Earnings per share-1.4

Dividend yield (TTM)—

Revenue (annual)52M

Net income (annual)-265.9M

Social

What share of all stock conversation is about OCUL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.04	0.01% +0.01	0% 0	0% +0

Sep 29

Ocular Therapeutix's (OCUL) stock price has decreased by ~20% following Kodiak Sciences' (KOD) Ph3 DAYBREAK data for Zenkuda, which some believe is an overreaction.
Analyst Piper Jaffray maintains a Buy recommendation on OCUL with a price target of $18, citing a favorable risk-reward profile despite the recent pullback.
OCUL's Helios 3 trial, which involves a new agreed-upon scale and comparison with a placebo, has a high probability of success at 85-90%, and the retinopathy market is expected to be a significant opportunity for the company.

Generated by AI

Sentiment

Of the messages about OCUL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5% +6.29	52.36% -29.31	63.46% -2.62	76.16% -7.72
Bearish	37.5% -6.29	47.64% +29.31	36.54% +2.62	23.84% +7.72

Bullish· Sep 28

$OCUL is undervalued, worth at least $2bn based on wAMD data alone, with additional value from MESI and 501.
The company's product has the best potential, with Ocular set to be the first to market and a strong recovery to $8.5 expected.
The market has overreacted, and $OCUL is a great bargain at current prices, with the company's strong product and potential for significant growth.

Bearish· Sep 28

The company's rival, Kodiak Pharmaceuticals, has released Phase 3 wet AMD data that matches Regeneron's Eylea, potentially threatening the company's FDA filing and market value.
The company's stock price has dropped significantly, with a 22.65% decline, and some investors are considering a buyout of Kodiak Pharmaceuticals as a way to offset losses.
The company's market capitalization has decreased, making it an attractive target for potential acquisitions, but Kodiak still needs to raise capital to fund its operations.

Generated by AI

Topics

Of the messages about OCUL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	35.29%	69.62%	69.11%	61.64%
Technical Analysis	0%	10.13%	6.28%	9.88%
Analysts	64.71%	20.25%	23.56%	18.95%
Controversies	0%	0%	1.05%	0.72%
Earnings	0%	0%	0%	3.7%
Macro	0%	0%	0%	5.1%

Earnings· Aug 7

Analysts expect Ocular Therapeutix, Inc. to report a loss of $0.37 per share.
Ocular Therapeutix, Inc. is hosting its Q2 earnings call today at 4:30pm Eastern.
The company's reported loss of $0.37 per share matches the consensus estimate.

Announcements· Jan 15

Sanofi is reportedly preparing a higher takeover offer for Ocular Therapeutix, after the company's board rejected an initial bid of $16 per share.
The improved bid is likely due to Ocular's late-stage drug AXPAXLI, which is being developed to treat wet AMD, a condition that affects millions of people worldwide.
Sanofi's takeover interest in Ocular has reignited buyout chatter and event-driven trading interest in the stock, with Ocular's shares surging in pre-market trading.

Controversies· Mar 21

Ocular Therapeutix, Inc. (OCUL) is being sued by EyePoint Pharmaceuticals (EYPT) for allegedly making false or misleading statements about EYPT's experimental eye drug.
The lawsuit, filed in a Massachusetts court, may lead to increased volatility and options activity in the sector.
The controversy surrounds EYPT's claims that OCUL's management was reckless in presenting safety data for a different drug, and that OCUL's CEO has made disparaging comments about EYPT's data.

Technical Analysis· Feb 13

$OCUL has hit long-term resistance around $6.10 and needs to break through with volume to move forward.
The stock is in an ascending triangle pattern, with a potential breakout above $5.00 resistance.
$OCUL has shown high relative strength and is expected to retest $6.12, with a potential parabolic move if it passes $6 again and holds the gain.

Generated by AI

Community

Of the messages about OCUL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.32%	87.53%	87.45%	63.83%
Newcomers	11.68%	12.47%	12.55%	36.17%

Regulars· Sep 29

Ocular Therapeutix's upcoming NDA is expected to be a significant catalyst for the stock, with regulars pointing to the company's strong results and durability of its product.
Regulars are comparing the performance of AXPAXLI and Zenkuda, with AXPAXLI demonstrating a clear advantage in terms of durability, and Zenkuda showing a slower decline in efficacy over time.
The retinopathy market is expected to grow significantly, with a potential market size of $12B+ by 2030, and Ocular Therapeutix is well-positioned to capture a significant share of this market with its lead product, Zenkuda.

Newcomers· Sep 28

The newcomer is adding to their position in $OCUL, expecting the stock to recover and reach $8.5.
The newcomer believes $OCUL is a bargain at its current price, having liquidated long-term ETFs to take advantage of the opportunity.
The newcomer is focused on scaling in and swinging for a few weeks if $OCUL doesn't recover to $8.5 today.

Generated by AI

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

6d agoYahoo Finance UK

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

7d agoYahoo Finance

New Ocular Therapeutix Target Price Amid Support

The small-cap firm is likely to see defense by professional managers.

11d agoTheStreet Pro

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12d agofinance.yahoo.com

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy

13d agoInvesting.com

Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI

14d agoInvesting.com

Also Discussed

Investors talking about OCUL also mention

#	Name	Attention
1	EyePoint, Inc. Common StockEYPT	0%0
2	Aurinia Pharmaceuticals IncAUPH	0.02%+0.01
3	Omeros Corp.OMER	0%+0
4	Regenxbio Inc.RGNX	0%+0
5	Clearside Biomedical Inc.CLSD	0%0
6	TG Therapeutics Inc.TGTX	0.01%+0
7	Autolus Therapeutics plc ADRAUTL	0%+0
8	Kura Oncology, Inc.KURA	0%+0
9	Kodiak Sciences Inc.KOD	0.07%-0.17
10	MRNS - Marinus Pharmaceuticals, Inc.	——

Ocular Therapeutix, Inc.

Healthcare
Biotechnology

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release therapies designed for ophthalmic use. Its current portfolio includes a marketed product for post-surgical ocular inflammation and pain, along with investigational therapies targeting retinal diseases, glaucoma, ocular hypertension, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix’s products and pipeline are centered on improving drug delivery in ophthalmology, where longer-acting formulations can help address treatment burden and support more consistent therapy administration. Based in Bedford, Massachusetts, the company operates in the specialty biopharmaceutical market with a strong emphasis on ocular care and retinal disease management.

Website

Location

14 Crosby Drive

Bedford, MA, 01730

United States

Social

What share of all stock conversation is about OCUL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.04	0.01% +0.01	0% 0	0% +0

Sep 29

Ocular Therapeutix's (OCUL) stock price has decreased by ~20% following Kodiak Sciences' (KOD) Ph3 DAYBREAK data for Zenkuda, which some believe is an overreaction.
Analyst Piper Jaffray maintains a Buy recommendation on OCUL with a price target of $18, citing a favorable risk-reward profile despite the recent pullback.
OCUL's Helios 3 trial, which involves a new agreed-upon scale and comparison with a placebo, has a high probability of success at 85-90%, and the retinopathy market is expected to be a significant opportunity for the company.

Generated by AI

Sentiment

Of the messages about OCUL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	62.5% +6.29	52.36% -29.31	63.46% -2.62	76.16% -7.72
Bearish	37.5% -6.29	47.64% +29.31	36.54% +2.62	23.84% +7.72

Bullish· Sep 28

$OCUL is undervalued, worth at least $2bn based on wAMD data alone, with additional value from MESI and 501.
The company's product has the best potential, with Ocular set to be the first to market and a strong recovery to $8.5 expected.
The market has overreacted, and $OCUL is a great bargain at current prices, with the company's strong product and potential for significant growth.

Bearish· Sep 28

The company's rival, Kodiak Pharmaceuticals, has released Phase 3 wet AMD data that matches Regeneron's Eylea, potentially threatening the company's FDA filing and market value.
The company's stock price has dropped significantly, with a 22.65% decline, and some investors are considering a buyout of Kodiak Pharmaceuticals as a way to offset losses.
The company's market capitalization has decreased, making it an attractive target for potential acquisitions, but Kodiak still needs to raise capital to fund its operations.

Generated by AI

Topics

Of the messages about OCUL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	35.29%	69.62%	69.11%	61.64%
Technical Analysis	0%	10.13%	6.28%	9.88%
Analysts	64.71%	20.25%	23.56%	18.95%
Controversies	0%	0%	1.05%	0.72%
Earnings	0%	0%	0%	3.7%
Macro	0%	0%	0%	5.1%

Earnings· Aug 7

Analysts expect Ocular Therapeutix, Inc. to report a loss of $0.37 per share.
Ocular Therapeutix, Inc. is hosting its Q2 earnings call today at 4:30pm Eastern.
The company's reported loss of $0.37 per share matches the consensus estimate.

Announcements· Jan 15

Sanofi is reportedly preparing a higher takeover offer for Ocular Therapeutix, after the company's board rejected an initial bid of $16 per share.
The improved bid is likely due to Ocular's late-stage drug AXPAXLI, which is being developed to treat wet AMD, a condition that affects millions of people worldwide.
Sanofi's takeover interest in Ocular has reignited buyout chatter and event-driven trading interest in the stock, with Ocular's shares surging in pre-market trading.

Controversies· Mar 21

Ocular Therapeutix, Inc. (OCUL) is being sued by EyePoint Pharmaceuticals (EYPT) for allegedly making false or misleading statements about EYPT's experimental eye drug.
The lawsuit, filed in a Massachusetts court, may lead to increased volatility and options activity in the sector.
The controversy surrounds EYPT's claims that OCUL's management was reckless in presenting safety data for a different drug, and that OCUL's CEO has made disparaging comments about EYPT's data.

Technical Analysis· Feb 13

$OCUL has hit long-term resistance around $6.10 and needs to break through with volume to move forward.
The stock is in an ascending triangle pattern, with a potential breakout above $5.00 resistance.
$OCUL has shown high relative strength and is expected to retest $6.12, with a potential parabolic move if it passes $6 again and holds the gain.

Generated by AI

Community

Of the messages about OCUL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.32%	87.53%	87.45%	63.83%
Newcomers	11.68%	12.47%	12.55%	36.17%

Regulars· Sep 29

Ocular Therapeutix's upcoming NDA is expected to be a significant catalyst for the stock, with regulars pointing to the company's strong results and durability of its product.
Regulars are comparing the performance of AXPAXLI and Zenkuda, with AXPAXLI demonstrating a clear advantage in terms of durability, and Zenkuda showing a slower decline in efficacy over time.
The retinopathy market is expected to grow significantly, with a potential market size of $12B+ by 2030, and Ocular Therapeutix is well-positioned to capture a significant share of this market with its lead product, Zenkuda.

Newcomers· Sep 28

The newcomer is adding to their position in $OCUL, expecting the stock to recover and reach $8.5.
The newcomer believes $OCUL is a bargain at its current price, having liquidated long-term ETFs to take advantage of the opportunity.
The newcomer is focused on scaling in and swinging for a few weeks if $OCUL doesn't recover to $8.5 today.

Generated by AI

Ocular Therapeutix

Social

Sep 29

Bullish· Sep 28

Bearish· Sep 28

Earnings· Aug 7

Announcements· Jan 15

Controversies· Mar 21

Technical Analysis· Feb 13

Regulars· Sep 29

Newcomers· Sep 28

Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

New Ocular Therapeutix Target Price Amid Support

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy

Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI

Also Discussed

Ocular Therapeutix, Inc.

Company Information

Location

Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

New Ocular Therapeutix Target Price Amid Support

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy

Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI

Also Discussed

Social

Sep 29

Bullish· Sep 28

Bearish· Sep 28

Earnings· Aug 7

Announcements· Jan 15

Controversies· Mar 21

Technical Analysis· Feb 13

Regulars· Sep 29

Newcomers· Sep 28